RayKnowChina Research Map
Shortlist0

Tianjin Medical University

天津医科大学

TianjinUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.3%Leads under 1 in 100 of China's research papers on NPC

Led 8 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025
ThemesRadiotherapy techniqueSide effects & quality of lifeImaging & AI

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital7
  2. Tianjin Medical University General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  2. Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China.2025BMC medicineFree full text
  3. Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma (NPC01) for head & neck cancer and health-related quality of life: a retrospective study.2022BMC complementary medicine and therapiesFree full text
  4. FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.2024Oral oncology
  5. The impact of submandibular glands protection on xerostomia as monitored by diffusion-weighted imaging in nasopharyngeal carcinoma patients.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Trials on ClinicalTrials.gov6
  1. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  2. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  3. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  4. Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal CarcinomaStatus unknownNCT04782765Lead sponsorPhase 2Start 2021-03
  5. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  6. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.9%Leads about 1 in 52 of China's research papers on ESCC ▲ from 1.2%

Led 56 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
12
Research papers it led
56
Trials it led
24
Share of China's trials
4.2%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025
ThemesImmunotherapyNeoadjuvant & combined treatmentRadiotherapy

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital47
  2. Tianjin Medical University General Hospital5
  3. Tianjin Medical University Second Hospital Counted in the group total1
  4. Tianjin Medical University Eye Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradia2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  2. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.2024Cancer cell
  3. Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.2025CancerFree full text
  4. Retrospective comparative study of video- and robot-assisted esophagectomy after neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.2025Surgical endoscopy
  5. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled,2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Lead sponsorPhase 2Start 2026-07
  2. Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07721103Lead sponsorPhase 2Start 2026-07
  3. Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Lead sponsorPhase 3Start 2026-03
  4. Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingNCT07457528Lead sponsorPhase 2Start 2026-03
  5. Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07493993Lead sponsorPhase 2Start 2026-06
  6. Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2Not yet recruitingNCT07531979Lead sponsorPhase 2Start 2026-04

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.0%Leads about 1 in 96 of China's research papers on HCC

Led 153 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
11
Research papers it led
153
Trials it led
37
Share of China's trials
2.5%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital88
  2. Tianjin Medical University General Hospital22
  3. Second Hospital of Tianjin Medical University Counted in the group total7
  4. Clinical School of the Second People's Hospital of Tianjin Medical University Counted in the group total7
  5. Chu Hsien-I Memorial Hospital4
  6. Tianjin Union Medical Center2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma.2022Gastroenterology
  2. Ominous Electrocardiographic Abnormalities in a Patient With Hepatocellular Carcinoma.2022JAMA internal medicine
  3. LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.2026European radiology
  4. Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study.2026Hepatology (Baltimore, Md.)Free full text
  5. Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Lead sponsorPhase 3Start 2026-06
  2. Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Lead sponsorPhase 2Start 2026-03
  3. Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCCRecruitingNCT07801287Lead sponsorPhase 2Start 2026-09
  4. Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCCNot yet recruitingNCT07847671Lead sponsorPhase 2Start 2026-10
  5. IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor ThrombusRecruitingNCT07799922Lead sponsorN/AStart 2026-05
  6. Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular CarcinomaRecruitingNCT07840092Lead sponsorStart 2026-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.2%Leads about 1 in 86 of China's research papers on Stomach cancer

Led 113 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
6
Research papers it led
113
Trials it led
37
Share of China's trials
2.5%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025
ThemesPeritoneal spread & advanced diseaseImaging & AIEarly detection & endoscopy

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital78
  2. Tianjin Medical University General Hospital30
  3. Second Hospital of Tianjin Medical University Counted in the group total3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.2024Cancer medicineRCTFree full text
  2. Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer.2021Cancer biology & medicineRCTFree full text
  3. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.2024Journal for immunotherapy of cancerFree full text
  4. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.2022Journal for immunotherapy of cancerFree full text
  5. Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.2026International journal of cancer
Trials on ClinicalTrials.gov6
  1. Laparoscopic Staging for Stage III Gastric CancerEnrolling by invitationNCT07533825Lead sponsorN/AStart 2025-02
  2. The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric CancerRecruitingNCT07183150Lead sponsorStart 2025-08
  3. A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)RecruitingNCT06506292Lead sponsorPhase 2Start 2024-07
  4. Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 OverexpressionRecruitingNCT06560528Lead sponsorPhase 2Start 2024-09
  5. Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingNCT06454435Lead sponsorPhase 2Start 2024-06
  6. A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric CancerRecruitingNCT04843215Lead sponsorN/AStart 2021-01

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.9%Leads about 1 in 51 of China's research papers on Hepatoblastoma ▲ from 1.2%

Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Tianjin Medical University General Hospital1
  2. Tianjin Medical University Cancer Institute & Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.7%Leads about 1 in 60 of China's research papers on Retinoblastoma ▲ from 0.9%

Led 5 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tianjin Medical University Eye Hospital4
  2. Tianjin Medical University General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
1.9%Leads about 1 in 53 of China's research papers on Chordoma New since 2021

Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.0%Leads about 1 in 98 of China's research papers on Osteosarcoma

Led 23 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital18
  2. Tianjin Medical University General Hospital3
  3. Tianjin Medical University Baodi Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.0%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▼ from 1.6%

Led 5 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital2
  2. Tianjin Medical University General Hospital2
  3. Second Hospital of Tianjin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.9%Leads about 1 in 52 of China's research papers on Neuroblastoma ▲ from 1.3%

Led 22 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
1
Research papers it led
22
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital21

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.5%Leads about 1 in 41 of China's research papers on Myeloma ▼ from 3.1%

Led 41 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
2
Research papers it led
41
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
ThemesDrug combinationsRelapse & resistanceDiagnosis, MRD & risk

Hospitals counted here

  1. Tianjin Medical University General Hospital27
  2. Tianjin Medical University Cancer Institute & Hospital10
  3. Second Hospital of Tianjin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.2025Journal for immunotherapy of cancerFree full text
  2. All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.2023Journal for immunotherapy of cancerFree full text
  3. Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma.2026Anti-cancer drugsFree full text
  4. A case of acute myeloid leukemia and multiple myeloma is observed to occur simultaneously.2025MedicineFree full text
  5. Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.2025Current treatment options in oncology
Trials on ClinicalTrials.gov6
  1. RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple MyelomaNot yet recruitingNCT07114432Lead sponsorPhase 1Start 2025-08
  2. The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Lead sponsorPhase 1/Phase 2Start 2024-11
  3. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  4. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  5. Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970Study siteStart 2024-12
  6. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025
ThemesCAR-T & cell therapyMRD & relapseChildren

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
5.6%Leads about 1 in 18 of China's research papers on Aplastic anaemia ▼ from 10.8%

Led 23 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
1
Share of China's trials
1.0%
Share of the world's papers
1.5%
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 0020242025: 112025
ThemesImmunosuppressive treatmentChildrenStem cell transplant

Hospitals counted here

  1. Tianjin Medical University General Hospital23

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
4.5%Leads about 1 in 22 of China's research papers on NMOSD ▼ from 10.9%

Led 22 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
2
Research papers it led
22
Trials it led
12
Share of China's trials
15.4%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
ThemesAntibodies & diagnosisBiologic drugsImaging

Hospitals counted here

  1. Tianjin Medical University General Hospital22

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease.2026Multiple sclerosis and related disorders
  2. Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.2025Journal of neurology
  3. Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder.2025Multiple sclerosis and related disorders
  5. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.2023Journal of neuroimmunology
Trials on ClinicalTrials.gov6
  1. Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderRecruitingNCT07420296Lead sponsorPhase 3Start 2026-01
  2. Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune DiseasesRecruitingNCT07022197Lead sponsorPhase 1/Phase 2Start 2025-04
  3. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  4. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingNCT05145361Study siteEarly phase 1Start 2022-04
  5. Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum DisorderActive, not recruitingNCT07184840Lead sponsorPhase 2Start 2025-09
  6. Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum DisordersWithdrawnNCT05909943Lead sponsorPhase 1/Phase 2Start 2024-06

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
1.6%Leads about 1 in 61 of China's research papers on IgG4-RD ▼ from 2.5%

Led 4 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025
ThemesDiagnosis & look-alikesHead, eye socket & salivary glandsTreatment & relapse

Hospitals counted here

  1. Tianjin Medical University General Hospital3
  2. Tianjin Medical University Eye Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
4.4%Leads about 1 in 23 of China's research papers on Myasthenia gravis

Led 22 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
22
Trials it led
2
Share of China's trials
2.2%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesThymus & thymectomyAntibodies & diagnosisBiologic & complement drugs

Hospitals counted here

  1. Tianjin Medical University General Hospital21
  2. Tianjin Baodi Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.8%Leads under 1 in 100 of China's research papers on Moyamoya

Led 3 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025
ThemesImaging & blood flowStroke & bleeding outcomesChildren

Hospitals counted here

  1. Tianjin Medical University General Hospital2
  2. Second Hospital of Tianjin Medical University Counted in the group total1
  3. Tianjin Medical University Cancer Institute & Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
2.3%Leads about 1 in 43 of China's research papers on Biliary atresia

Led 5 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025
ThemesLiver transplantComplications after surgeryLong-term outcomes

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.9%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 9 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tianjin Medical University General Hospital7
  2. Second Hospital of Tianjin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis.2025European journal of pharmacology
  2. SIRT5-mediated desuccinylation prevents mitochondrial dysfunction in alveolar epithelial cells senescence and pulmonary fibrosis.2025Cellular signalling
  3. Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis.2025Respirology (Carlton, Vic.)
  4. Identification and validation of CDC20 and ITCH as ubiquitination related biomarker in idiopathic pulmonary fibrosis.2025Hereditas
  5. The histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.4%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Tianjin Medical University General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
2.4%Leads about 1 in 43 of China's research papers on Duchenne muscular dystrophy ▼ from 4.1%

Led 5 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tianjin Medical University General Hospital2
  2. Second Hospital of Tianjin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.5%Leads about 1 in 67 of China's research papers on IgA nephropathy ▼ from 2.6%

Led 11 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. Tianjin Medical University General Hospital10
  2. Second Hospital of Tianjin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
5.1%Leads about 1 in 20 of China's research papers on Osteogenesis imperfecta ▲ from 1.5%

Led 5 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 002025

Hospitals counted here

  1. Tianjin Medical University General Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
3.0%Leads about 1 in 33 of China's research papers on Primary biliary cholangitis ▲ from 1.3%

Led 9 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Hospitals counted here

  1. Tianjin Medical University General Hospital7
  2. Clinical School of the Second People's Hospital of Tianjin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.2%Leads about 1 in 81 of China's research papers on Hirschsprung disease ▼ from 2.2%

Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
1.7%Leads about 1 in 59 of China's research papers on Familial adenomatous polyposis ▼ from 5.9%

Led 1 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Tianjin Medical University Cancer Institute & Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
5.8%Leads about 1 in 17 of China's research papers on Leber hereditary optic neuropathy ▲ from 2.4%

Led 3 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Tianjin Medical University General Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov